Tag Archives: drug resistance

Modulight Spotlights: LASER-SHARP RESEARCH – September 2024

September 23, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – September 2024 University of Maryland and Modulight have published together a new research study about the mechanisms of cancer drug resistance. Drug resistance is a leading cause of treatment failure and often has dramatic consequences for survival of cancer patients. Cancer cells have developed various ways to protect themselves from drugs. When several clinically used photoactive drugs were studied, it was shown that some of them were being actively pumped out by cancer cells, thus likely limiting the full therapeutic potential Continue reading →

Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions in vitro

September 20, 2024 by Modulight Content
No comments
Published in: Cancer Drug Resistance Authors: Shruti Vig1, Payal Srivastava1,#, Idrisa Rahman1,2,#, Renee Jaranson1, Anika Dasgupta1, Robert Perttilä3, Petteri Uusimaa3, Huang-Chiao Huang1  Published in: Cancer Drug Resistance Authors: Shruti Vig1, Payal Srivastava1,#, Idrisa Rahman1,2,#, Renee Jaranson1, Anika Dasgupta1, Robert Perttilä3, Petteri Uusimaa3, Huang-Chiao Huang1 University of Maryland and Modulight have published together a new research study about the mechanisms of cancer drug resistance. Drug resistance is a leading cause of treatment failure and often has dramatic consequences for survival of cancer patients. Cancer cells have developed various ways to protect themselves from drugs. When several clinically used photoactive drugs were studied, it was shown that some of them were being actively pumped out by cancer cells, thus likely limiting the full therapeutic potential of these Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – November 2023

November 14, 2023 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – November 2023 The development of modern antibiotics is recognized as one of the major achievements of medicine and has saved millions of lives. However, many infectious agents have developed resistance to antibiotics over time, and defining new antibiotic targets has been difficult since very few genes are essential for pathogens. To combat this growing problem, Professor Timothy Haystead’s team at Duke University developed a novel light-based antimicrobial strategy that targets non-essential enzyme on the surface of bacteria. Light activation was Continue reading →

Targeting Borrelia burgdorferi HtpG with a berserker molecule, a strategy for anti-microbial development

November 1, 2023 by Modulight Content
No comments
Published in: Cell Chemical Biology Authors: Dave L. Carlson, Mark Kowalewski, Khaldon Bodoor, Matthew R. Redinbo, Neil Spector, Timothy A.J. Haystead Duke UniversityPublished in: Cell Chemical Biology Authors: Dave L. Carlson, Mark Kowalewski, Khaldon Bodoor, Matthew R. Redinbo, Neil Spector, Timothy A.J. Haystead Duke University Conventional antimicrobial discovery relies on targeting essential enzymes in pathogenic organisms, contributing to a paucity of new antibiotics to address resistant strains. Here, by targeting a non-essential enzyme, Borrelia burgdorferi HtpG, to deliver lethal payloads, we expand what can be considered druggable within any pathogen. We synthesized HS-291, an HtpG inhibitor tethered to the photoactive toxin verteporfin. Reactive oxygen species, generated by light, enables Continue reading →